Filing identity and period
The supplied 10-Q identifies the registrant as PerkinElmer, Inc. (NYSE: PKI), not Revvity, Inc. It reports the quarter and six months ended July 3, 2022, with comparisons to periods ended July 4, 2021. Verify that this is the intended filing for the requested company.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $1,229.6 million | $1,228.5 million | $2,489.0 million | $2,536.2 million |
| Gross margin | 54.2% | 55.8% | 54.1% | 58.0% |
| Operating income | $250.9 million | $332.5 million | $505.7 million | $800.3 million |
| Net income | $179.2 million | $245.9 million | $356.2 million | $625.2 million |
| Diluted EPS | $1.42 | $2.19 | $2.81 | $5.56 |
| Operating cash flow | Not separately stated | Not separately stated | $380.7 million | $761.4 million |
Q2 revenue was essentially flat: 29% growth in Discovery & Analytical Solutions was offset by a 20% decline in Diagnostics. The Diagnostics decline reflected lower COVID-19-related revenue; the company reported that COVID-19 product revenue fell $143.5 million year over year in Q2 and $383.7 million in the first half. Product revenue rose to $816.1 million in Q2, while service revenue fell to $413.5 million.
Q2 operating margin declined to approximately 20.4% from 27.1%. Management cited lower COVID-19 revenue, acquired-intangible amortization, and investment in product development and growth. Gross margin was pressured by acquisition-related amortization and inventory purchase-accounting charges, as well as supply-chain disruption and inflation.
Cash, debt, and liquidity
At July 3, 2022, cash and cash equivalents were $360.9 million, down from $618.3 million at January 2, 2022. Total debt carrying value, including current debt, was approximately $4.49 billion, down from $4.98 billion. The company reported $1.5 billion of unused capacity under its revolving credit facility and repaid $450 million of its term loan during the first half; it expected to repay the remaining $50 million in the second half of fiscal 2022.
First-half operating cash flow declined by $380.7 million year over year, which management attributed to lower profitability and greater working-capital use. Investing cash outflow was $84.7 million, including $52.6 million of capital expenditures. Financing cash outflow was $519.5 million, including debt repayments, $56.0 million of share repurchases, and $17.7 million of dividends.
Material changes, outlook, and risks
- The company recognized $117.8 million of revenue in Q2 from the remaining nonrefundable prepayment under its California Department of Public Health COVID-19 testing contract, which ended as the Valencia laboratory closed.
- On August 1, 2022, the company announced an agreement to divest its Analytical, Food and Enterprise Services businesses for $2.45 billion: $2.30 billion at closing and $150 million contingent on the buyer’s future exit valuation. Closing was expected in the first quarter of fiscal 2023, subject to approvals and customary conditions.
- Management anticipated continued supply-chain disruption and inflation through the remainder of fiscal 2022; these factors increased Q2 cost of goods sold by approximately $10 million year over year. The filing provides no clear numerical full-year revenue or earnings guidance.
- Key disclosed risks include declining COVID-19 demand, supply and logistics constraints, inflation, foreign-exchange movements, acquisition integration and divestiture execution, substantial debt, and potential impairment of significant goodwill and intangible assets.
- Environmental remediation accruals were $12.1 million. Management did not expect environmental matters or other ordinary-course legal contingencies to have a material adverse effect, while noting outcomes remain uncertain.
- Other notable items: first-half foreign-currency translation losses were $296.4 million; quarterly dividends were $0.07 per share. A new $300 million share-repurchase authorization was approved after quarter-end.
Important facts for investors to verify
- Confirm the registrant: the filing text is for PerkinElmer, Inc. (PKI), not Revvity, Inc.
- Assess how much reported performance depends on COVID-19 testing demand and the one-time $117.8 million CDPH prepayment recognition.
- Review the proposed $2.45 billion divestiture’s closing conditions, contingent proceeds, and effects on the continuing business and debt reduction.
- Track cash conversion and working-capital needs alongside debt repayment, repurchases, and dividends.
- Evaluate continued supply-chain and inflation pressures, acquisition-related amortization and costs, and the sensitivity of goodwill and intangible assets to business performance.